..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Mild cognitive impairment Alzheimer’s disease Cognition Computerized...

...Julie Carrier-Auclair; Monica Lavoie; Maud Tastevin; Robert Laforce Jr. Introduction: For over 25 years, cholinesterase inhibitors (ChEIs) have been the main symptomatic treatment for Alzheimer’s disease (AD). Several meta-analyses have supported their effectiveness in various neurocognitive...

... populations have been lacking. Methods: This open-label, multicenter, single-arm, phase IV trial enrolled 150 patients aged ≥50 years with major neurocognitive disorder due to Alzheimer’s disease, major vascular neurocognitive disorder, or mixed forms of both according to the Diagnostic and Statistical Manual...

... impairment Alzheimer’s disease Epidemiology Mexico Aging is a process that involves different aspects such as biological, psychological, and social features, which together lead to the development of age-related diseases [ 1, 2 ]. Among these, mild cognitive impairment (MCI) is a neurocognitive...

... Dementia with Lewy bodies Alzheimer’s disease Frontotemporal dementia Caregiver burden can be understood as a multidimensional concept that refers to the caregiver’s perceived level of strain from caring for a patient over time [ 1 ], and it has been associated with negative outcomes...

...Lucas Nogueira de Carvalho Pelegrini; Vanessa Alexandre da Silva; Marina Mantellatto Grigoli; Izabela Pereira Vatanabe; Patricia Regina Manzine; Marcia Regina Cominetti Introduction: Low educational attainment is a potential risk factor for Alzheimer’s disease (AD) development. Alpha-secretase...

...Ping Lin; Jiandong Wang; Yuyan Li; Guofeng Li; Ying Wang Introduction: The objective of the study was to explore the molecular mechanism of long noncoding RNA (lncRNA) LINC00472 in Alzheimer’s disease (AD) and identify potential novel targets for AD therapy. Method: Ferroptosis-related lncRNAs were...

...Nilton Custodio; Marco Malaga; Rosa Montesinos; Diego Chambergo-Michilot; Fiorella Baca; Juan Carlos Carbajal; Jose Carlos Huilca; Eder Herrera-Perez; David Lira; Monica M. Diaz; Serggio Lanata Introduction: As disease-modifying therapies become available for Alzheimer’s disease (AD), detection...

...Anna-Lena Richter; Marlies Diepeveen-de Bruin; Michiel G.J. Balvers; Lisette C.P.G.M. De Groot; Peter Paul De Deyn; Sebastiaan Engelborghs; Renger F. Witkamp; Yannick Vermeiren Introduction: Studies suggest a role of vitamin D in the progression and symptomatology of Alzheimer’s disease (AD...

... of 8,330.6 person-years of follow-up, 101 persons were diagnosed with dementia, including 74 with Alzheimer's disease (AD) and 26 with vascular dementia (VaD). The high (vs. low) tertile of lifelong CR score was associated with multivariable-adjusted hazards ratios (95% confidence interval) of 0.28 (0.14...

...Maoni Jia; Yafei Wu; Chaoyi Xiang; Ya Fang Introduction: This study aimed to develop novel machine learning models for predicting Alzheimer’s disease (AD) and identify key factors for targeted prevention. Methods: We included 1,219, 863, and 482 participants aged 60+ years with only...

...Lijuan Tang; Zhenglin Zhang; Feifan Feng; Li-Zhuang Yang; Hai Li Introduction: Alzheimer’s disease (AD) is the most prevalent type of dementia and can cause abnormal cognitive function and progressive loss of essential life skills. Early screening is thus necessary for the prevention...

...Rui Wang; Yi Zhu; Lan-Fang Qin; Zhi-Guo Xu; Xi-Ren Gao; Chong-Bin Liu; Guo-Tong Xu; Yi-Zhu Chen Introduction: Stem cell-based regenerative medicine has provided an excellent opportunity to investigate therapeutic strategies and innovative treatments for Alzheimer’s disease (AD). However...

...Jonathan P Scott; Donnchadh F Murphy; Rupert F Noad Introduction: Visual and spatial perception (VSP) are cognitive domains frequently assessed in the screening and neuropsychological assessment of dementia. Evidence suggests that VSP impairment is common in the early stages of Alzheimer’s disease...

... Alzheimer’s disease (AD) risk. Although brain amyloid load is a recognized hallmark of pre-symptomatic AD, its relationship to increased BP is less known. The objective of this study was to examine the relationship of BP to brain estimates of amyloid-β (Aβ) and standard uptake ratio (SUVr). We hypothesized...

..., the incidence of epilepsy in patients with Alzheimer’s disease (AD) is increasing, drawing attention to the pathological relationship between the two conditions. Clinical studies have suggested the protective action of antiepileptic agents on dementia; however, the underlying mechanism remains unknown. We...

.... Social connectedness Nursing homes Facility factors Alzheimer’s disease Dementia National Institutes of Health (NIH) 10.13039/100000002 Of people with Alzheimer’s disease and other related dementias (ADRD), three quarters will spend time in nursing homes before 80 years of age...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Activities of daily living Alzheimer’s disease Discrepancy scores Insight Anosognosia Wellcome Trust 10.13039...

... Introduction: Several recent research studies show high performance of blood biomarkers to identify Alzheimer’s disease also in the pre-dementia mild cognitive impairment (MCI) stage, but data from the routine clinical care memory clinic setting are needed. Methods: We examined plasma samples of 144 memory...

... in patients with Alzheimer’s disease (AD). However, no studies have examined its relationship with AD-related biomarkers. Methods: One-hundred twenty-one older adults (intact, amnestic mild cognitive impairment, mild AD) completed the QDRS, and three biomarkers (amyloid deposition via positron emission...